Rani Therapeutics Holdings, Inc. Class A (RANI)
NASDAQ:RANI
Want to see RANI full AI Analyst Report?
RANI Stock Chart & Stats
$0.96
-$0.04(-3.15%)
At close: 4:00 PM EST
$0.96
-$0.04(-3.15%)
Day’s Range― - ―
52-Week Range$0.39 - $3.87
Previous CloseN/A
Volume228.85K
Average Volume (3M)1.07M
Market Cap
$95.15M
Enterprise Value$44.28M
Total Cash (Recent Filing)$43.40M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding99,912,510
10 Day Avg. Volume821,558
30 Day Avg. Volume1,066,136
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue13.97
Enterprise Value/Gross Profit14.72
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$7.50Price Target Upside681.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$2.42M
Bulls Say, Bears Say
Bulls Say
Platform & Pipeline (RaniPill)Rani's ingestible delivery platform (RaniPill) addresses a structural limitation for biologics by enabling oral dosing. Demonstration via a Phase 1 RT-114 collaboration with ProGen validates technical feasibility and creates a durable competitive advantage that can drive sustained partner interest and long-term licensing opportunities.
Manageable Leverage & Meaningful RunwayLow leverage and positive equity improve financial flexibility versus prior periods, and reported cash balances plus the recent $20M financing extend runway. This structural funding buffer reduces near-term refinancing pressure, enabling continued clinical development and partnership execution without immediate dilution.
External Collaborations & Milestone PotentialActive collaborations (Chugai, ProGen) create non-dilutive funding avenues through milestone payments and validate platform utility to third parties. Durable partner relationships diversify funding streams and can accelerate development timelines, lowering reliance on equity raises for long-term program advancement.
Bears Say
Persistent Cash Burn & LossesSustained negative operating and free cash flow indicates the business continues consuming capital to fund R&D and operations. Without material revenue or milestone inflows, ongoing burn necessitates further external financing, raising dilution risk and potentially constraining R&D prioritization or timelines if funding gaps arise.
Very Small, Declining Revenue BaseRevenue remains nascent and declined year-over-year, signaling the company has not achieved commercial traction. A tiny, volatile revenue base limits internal funding capacity, makes unit economics unproven at scale, and keeps the business dependent on partnerships and capital markets for sustained operation.
Nasdaq Bid-price Noncompliance & CFO TransitionListing noncompliance risk can force structural actions (reverse split or transfer) that affect liquidity and investor base. Concurrent CFO departure during critical financing and trial stages elevates execution and governance risk, potentially disrupting financial strategy and investor confidence at a pivotal development juncture.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $0.39 and its highest was $3.87 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $95.15M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 49 days.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Rani Therapeutics Holdings, Inc. Class A released its earnings results on May 15, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.045 by $0.005.
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.05.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 99,912,510 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Rani Therapeutics Holdings, Inc. Class A reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.045. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (681.25% Upside)
$7.50 (681.25% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.96%
12-Months-Change
Fundamentals
Return on Equity
-245.45%
Trailing 12-Months
Asset Growth
115.04%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
RANI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.View all RANI earnings summariesRANI Stock 12 Month Forecast
Average Price Target
$7.50
▲(681.25% Upside)
Technical Analysis
Ownership Overview
27.78% Insiders
5.45% Mutual Funds
33.78% Other Institutional Investors
28.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---